Source: Annual Congress 2012 - Treatment of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
J. Skrickova, K. Hejduk, Z. Bortlicek, M. Pesek, V. Kolek, L. Koubkova, P. Zatloukal, F. Salajka, M. Zemanova, D. Sixtova, J. Roubec, H. Coupkova (Brno, Plzen, Olomouc, Praha, Hradec Kralove, Ostrava, Czech Republic). Pemetrexed in the first line treatment in non-small cell lung cancer (NSCLC): A multicentre prospective analysis of data from clinical practise of Czech Republic. Eur Respir J 2012; 40: Suppl. 56, 2915

Member's Comments

No comment yet.

Related content which might interest you: Cost-effectiveness analysis of three strategies of erlotinib treatment in non small-cell lung cancer: A prospective multicentric French study (ERMETIC) Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Pembrolizumab versus nivolumab as second and further line treatment in non-small cell lung cancer; a retrospective single-centre study Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Palliative chemotherapy in non-small cell lung cancer (NSCLC): analysis of UK baseline data from the ACTION observational study Source: Eur Respir J 2005; 26: Suppl. 49, 11s Year: 2005 Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): the MRC LU22/NVALT/EORTC 08012 multi-centre randomised trial Source: Eur Respir J 2007; 30: Suppl. 51, 240s Year: 2007 The big lung trial (BLT): a major randomised trial examining the role of cisplatin-based chemotherapy in all stages of non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002 Use of erlotinib in management of advanced non-small cell lung cancer (NSCLC): The Czech Republic experience with the treatment of a non-selected population of 1735 patients (pts) Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011 Bevacizumab as first line treatment for advanced non-small cell lung cancer (NSCLC): a meta-analysis of randomised placebo-controlled trials (RCTs) Source: Annual Congress 2008 - Therapy in thoracic oncology Year: 2008 A multicenter phase II study of carboplatin/vinorelbine in advanced non-small cell lung cancer (NSCLC) in elderly patients (GFPC 9902) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003 Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I – IIIa nonsmall cell lung cancer conducted by the European lung cancer working party Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003 Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Tyrosine-kinase inhibitors (TKI) in first-line treatment of patients with non-small cell lung cancer (NSCLC) - real life data from the Czech Republic. Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Efficacy and safety of nivolumab in routine NSCLC treatment – an observational study in 5 lung cancer centers in Berlin, Germany Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study Source: Eur Respir J 2007; 29: 128-133 Year: 2007 Advanced non-small cell lung cancer (NSCLC): observation of chemotherapy in 5 European countries Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 The selective EGFR tyrosine-kinase inhibitor erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) – a single institution experience of TRUST – a worldwide open label non randomized phase IV trial Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 A study comparing the efficacy, quality of life and toxicity of cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer in the Indian scenario Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients Year: 2011 Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Phase II open-label trial of erlotinib in progressive pretreated advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Radiation therapy for augmenting the efficacy of immunotherapy in advanced non-small cell lung cancer: a case-controlled study Source: ERJ Open Res, 6 (1) 00189-2019; 10.1183/23120541.00189-2019 Year: 2020